Minor groove binders 1998 – 2004

Bibliography

• REDDY BP, SONDHI SM, LOWN JVV: Synthetic DNA minor groove-binding drugs. Pharmacol. Therap. (1999) 84:1–111.
   PubMed Web of Science ®Google Scholar
• ••A primary source reference to the literatureof MGBs, especially with respect to structure—binding and structure—activity relationships.
   Google Scholar
• ARCAMONE FM, ANIMATI F, BARBIERI B et al.: Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. Med . Chem. (1989) 32:774–778.
   Web of Science ®Google Scholar
• FINLAY AC, HOCHSTEIN FA, SOBIN BA et al.: Netropsin, a new antibiotic produced by a Streptomyces. Am. Chem. Soc. (1951) 73:341.
   Web of Science ®Google Scholar
• GREHN L, RAGNARSSON U, ERIKSSON B et al.: Synthesis and antiviral activity of distamycin A analogues: substitutions on the different pyrrole nitrogens and in the amidine function. Med . Chem. (1983) 26:1042–1049.
   Web of Science ®Google Scholar
• •Key reference that shows the cellular activity of MGBs.
   Google Scholar
• SHARMA SK, BILLAUD J-N, TANDON M et al.: Inhibition of feline immunodeficiency virus (FIV) replication by DNA binding polyamides. Bioorg. Med. Chem. Lett. (2002) 12:2007–2010.
   PubMed Web of Science ®Google Scholar
• •Key reference that shows the cellular activity of MGBs.
   Google Scholar
• DICKINSON LA, GULIZIA RJ, TRAUGER JW et al.: Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Nati Acad. ScL USA (1998) 95:12890–12895.
   PubMed Web of Science ®Google Scholar
• •Key references that shows the cellular activity of MGBs.
   Google Scholar
• BAILLY C, CHAIRES JB: Sequence specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bioconjug. Chem. (1998) 9:513–538.
   Google Scholar
• •Key references that shows the cellular activity of MGBs.
   Google Scholar
• HANKA LJ, DIETZ A, GERPHIEDE SA, et al.: CC-1065 (NSC-298223), anew antitumour antibiotic: production, in vitro biological activity, microbial assays, and taxonomy of producing organisms. Antibiot . (1978) 31:1211–1217.
   Google Scholar
• LEMGRUBER W, BATCHO AD, SCHENKER F: The structure of anthramycin. J. Am. Chem. Soc. (1965) 87:5793–5795.
   PubMed Web of Science ®Google Scholar
• HARSHMAN ICD, DERVAN PB: Molecularrecognition of DNA by Hoechst 33258. Nuclek Acids Res (1985) 13:4825–4835.
   PubMed Web of Science ®Google Scholar
• UMETSKAIA VN, RZANOV, IM: Mechanism of interaction of DNA with the fluorescent dye, Hoechst 33258. Biofizika (1990) 35:399–401.
   PubMed Web of Science ®Google Scholar
• DAN 0, BERGEN G, DERMANT E, et al: Trypanocide diamidine of 2-phenylbenzofurans, 2-phenylindene and 2-phenylindole. Liebigs Ann. Chem. (1971) 749:68–89.
   Google Scholar
• KAYSER K, BAUMGARTNER K, GABIUS HJ: Cytometry with DAPI-stained tumor imprints. Anal. Qualm Cytol. Histol (1996) 18:115–120.
   PubMedGoogle Scholar
• DERVAN PB: Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. (2001) 9:2215–2235.
   PubMed Web of Science ®Google Scholar
• ••A concise and informative exposition ofthe selectivity rules for oligoamide MGBs binding to DNA with detailed structural Information.
   Google Scholar
• TABERNO L, VERDAGAUER N, COLL M et al: Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug, netropsin. Biochemistry (1993) NN-8403 (Protein Data Bank code 121D).
   Google Scholar
• MITRA SN, WAHL MC, SUNDARALINGAM, M: Structure of side by side binding of distamycin to d(GTATATAC)2. Acta Cryst. D. (1999) 55:602-609 (Protein Data Bank code 378D).
   Google Scholar
• TSE WC, TAKAHIRO I, BOGER DL: Comprehensive high-resolution analysis of hairpin polyamides utilizing a fluorescent intercalator displacement (FID) assay. Bioorg. Med. Chem. (2003) 11: 4479–4486.
   PubMed Web of Science ®Google Scholar
• ANTHONY N, MACKAY SP, WAIGH RD et al.: A highly predictive model of ligand binding to the minor groove of DNA. Submitted.
   Google Scholar
• GAVATHIOTIS E, SHARMAN DJ, SEARLE MS: Sequence dependent variation in DNA minor groove width dictates orientational preference of Hoechst 33258 in A-tract recognition: solution NMR of the 2:1 complex with d(CTITTGCAAAAG)2. Nucleic Acids Res. (2000) 28:728
   PubMed Web of Science ®Google Scholar
• TRAUGER JW, BAIRD EE, DERVAN PB:Recognition of DNA by designed ligands at subnanomolar concentrations. Nature (1996) 382:559–561.
   PubMed Web of Science ®Google Scholar
• GEIERSTANGER BH, MRKSICH M, DERVAN PB et al: Design of a G.0 specific DNA minor groove binder. Science (1994) 266:646–650.
   Google Scholar
• SHARMA SK, TANDON M, LOWN JW: Design and synthesis of new thiazolated cross-linked DNA binding polyamides for altered sequence recognition. Tetrahedron (2002) 58:3417–3421.
   Web of Science ®Google Scholar
• BUGREEV DV, VASYUTINA EL, RYABININ VA et al: Inhibition of human DNA topoisomerase I by new DNA minor groove ligands: derivatives of oligo-1,3-thiazolocarboxamides. Antisense Nucleic Acid Drug Dev. (2001) 11:137–147.
   PubMedGoogle Scholar
• PLOUVIER, B, HOUSSIN R, HECQUET B et al: Antitumour combilexin, a thiazole containing analogue of netropsin linked to an acridine chromophore. Bioconjug. Chem. (1994) 5:475–481
   PubMed Web of Science ®Google Scholar
• URBACH AR, SZEWCZYK JW, WHITE S et al.: Sequence selectivity of 3-hydroxypyrrole/pyrrole ring pairings in the DNA minor groove. J. Am. Chem. Soc. (1999) 121:11621–11629.
   Web of Science ®Google Scholar
• ELLERVIK U, WANG CC, DERVAN PB: Hydroxybenzamide/pyrrole pair distinguishes T.A from A.T base pairs in the minor groove of DNA. J. Am. Chem. Soc. (2000) 122:9354–9360.
   Web of Science ®Google Scholar
• BUERLI RW, GE Y, WHITES et al: DNA binding ligands with excellent antibiotic potency against drug-resistant Gram-positive bacteria. Bioorg. Med. Chem. Lett. (2002) 12:2591–2594
   PubMed Web of Science ®Google Scholar
• SOLA F, FARAO M, PESENTI E et al.: Antitumour activity of FCE 26644, a new growth factor complexing molecule. Cancer Chemother. Pharmacol (1995) 36:217–222.
   PubMed Web of Science ®Google Scholar
• CLANTON DJ, BUCKHEIT RW JR TERPENING SJ et al: Novel sulfonated and phosphonated analogues of distamycin which inhibit the replication of HIV. Antiviral Res. (1995) 27:335–354.
   PubMed Web of Science ®Google Scholar
• SATZ AL, BRUICE TC: Recognition in theminor groove of double stranded DNA by microgonotropens. Accts. Chem. Res. (2002) 35:86–95.
   PubMed Web of Science ®Google Scholar
• GOTTESFELD JM, MELANDER C, SUTO RK et al. Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. I Mol. Biol. (2001) 309:615–629.
   Google Scholar
• DUD OUET B, BURNETT R, DICKINSON LA et al: Accessibility of nuclear chromatin by DNA binding polyamides. Chem. Biol. (2003) 10:859–867.
   PubMedGoogle Scholar
• CROWLEY KS, PHILLION DP: WOODARD SS et al: Controlling the intracellular localisation of fluorescent polyamide analogues in cultured cells. Bioorg. Med. Chem. Lett. (2003) 13:1565–1570.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, MORRISSEY AT, MILLER GG et al.: Design, synthesis, and intracellular localisation of a fluorescently labeled DNA binding polyamide related to the antibiotic distamycin. Bioorg. Med. Chem. Lett. (2001) 11:769–772.
   PubMed Web of Science ®Google Scholar
• MAESHIMA K, JANSSEN S, LAEMMLI UK: Specific targeting of insect and vertebrate telomeres with pyrrole and imidazole polyamides. EMBO J. (2001) 20:3218–3228.
   PubMed Web of Science ®Google Scholar
• KUMAR S, YADAGIRI B, ZIMMERMANN J et al.: Sequence specific molecular recognition and binding by a GC recognising Hoechst 33258 analogue to the decadeoxyribonucleotide cl[CATGGCCATG]2: structural and dynamic aspects deduced from high field 1H NMR studies. J. Biomol. Struct. Dyn. (1990) 8:331–357.
   PubMed Web of Science ®Google Scholar
• SINGH MP, JOSEPH T, KUMAR S et al: Synthesis and sequence specific DNA binding of a topoisomerase inhibitory analogue of Hoechst 33258 designed for altered base and sequence recognition. Chem. Res. Toxicol (1992) 5:597–507.
   PubMed Web of Science ®Google Scholar
• BARCELLONA ML, GRATTON E: The fluorescence properties of a DNA probe, 4',6-diamidino-2-phenylindole complex. Biochim. Biophys. Acta (1990) 993:174–178.
   Google Scholar
• JANSEN K, LINCOLN P, NORDEN B: Binding of DAPI analogue 2,5-bis(4-amidinophenyflfuran to DNA. Biochemistry (1993) 32:6605–6612.
   PubMed Web of Science ®Google Scholar
• TRENT JO, CLARK GR, KUMAR A, et al.: Targeting the minor groove of DNA. Crystal structures of two complexes between furan derivatives of berenil and the DNA dodecamer d(CGCGAATTCGCG)2. J. Med. Chem. (1996) 39:4554–4562.
   Google Scholar
• ANTHONY NG, FOX KR, JOHNSTON F et al.: DNA binding of a short lexitropsin. Bioorg. Med. Chem. Lett. (2004) 14:1353–1356.
   PubMed Web of Science ®Google Scholar
• SUCKLING CJ: The cyclopropyl group in studies of enzyme mechanism and inhibition. Angew. Chem. Int. Edn. Engl. (1988) 27:537–552.
   Web of Science ®Google Scholar
• BOGER DL, JOHNSON DS, YUN W et al.: Molecular basis for sequence selective alkylation of DNA by (-0- and ent ( ) CC 1065 and related agents: alkylation site models that accommodate the offset AT rich adenine N3 selectivity. Bioorg. Med. Chem. (1994) 2:115–135.
   PubMedGoogle Scholar
• PIERCE JR, ZAZIMIEC M, TANG TS: Comparison of sequence preference of tomamycin and anthramycin - DNA bonding by exonuclease III and exonuclease digestion and UVrABC nuclease incision analysis. Biochemistry (1993) 32:7069–7078.
   PubMed Web of Science ®Google Scholar
• KHALAF Al, PITT AR, SCOBIE M et al: The synthesis of some head to head linked DNA minor groove binders. Tetrahedron (2000) 56: 5225–5239.
   Web of Science ®Google Scholar
• KHALAF Al, PITT AR, SCOBIE M et al: Synthesis of novel DNA binding agents: indole-containing analogues of bis netropsin. ./. Chem. Res. (2000) 264–265.
   Google Scholar
• KHALAF Al, EBRAHIMABADI AR, DRUMMOND AL et al.: Synthesis and antimicrobial activity of some netropsin analogues. Org. Biomol. Chem. in press.
   Google Scholar
• DYATKINA NB, ROBERTS CD, KEICHER JD, et al: Minor groove binders as antibacterial agents. 1. Pyrrole tetraamides are potent antibacterial agents against vancomycin resistant Enterococci and methicillin resistant Staphyllococcus aureus. Med . Chem. (2002) 45:805–817.
   Google Scholar
• KHALAF Al, WAIGH RD, DRUMMOND AJ et al.: Distamycin analogues with enhanced lipophilicity. J. Med. Chem. (2004) 47:2133–2156.
   PubMed Web of Science ®Google Scholar
• JAMES PL, MERKINA E, KHALAF Al, et al.: DNA sequence recognition by an isopropyl substituted thiazole polyaamide: Nucleic Acid. Res. (2004) 32:3410–3417.
   Google Scholar
• PARKINSON JA, KHALAF Al, MACKAY SP et al. NMR studies of a short lexitropsin: DNA minor groove binding complex: sequence specificity for 5'HACTAGT-3'. I Am. Chem. Soc. Doi10.1021/ja030658n.
   Google Scholar
• KHALAF Al, PITT AR, SCOBIE M et al.: DNA binding, solubility, and partitioning characteristics of extended lexitropsins. J. Med. Chem. (2000) 43:3257–3266.
   PubMed Web of Science ®Google Scholar
• BROYLES S, KREMER M, KNUTSON BA: Antiviral activity of distamycin A against vaccinia virus is the result of inhibition of postreplicative mRNA synthesis. J. Virol. (2004) 78:2137–2141.
   PubMed Web of Science ®Google Scholar
• COZZI P: The discovery of a new potential anticancer drug: a case history. II Farmaco (2003) 58:213–220.
   PubMedGoogle Scholar
• •• One of the few descriptions of theevolution of a genuine drug target in the MGB field.
   Google Scholar
• TEN TUE AJ, VERWEIJ J, SPARREBOOM A et al: Phase land pharmacokinetic study of brostacillin (PNU-166196), a new DNA minor groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin. Cancer Res. (2003) 9:2957–2964.
   PubMed Web of Science ®Google Scholar
• FEDIER A, FOWST C, TURSI J et al: Brostacillin (PNU-166196) - a new DNA minor groove binder retains sensitivity in DNA mismatch repair-deficient tumour cells. BE J. Cancer (2003) 89:1559–1565.
   Web of Science ®Google Scholar
• FOSTER BJ, DEKNONING TF, KELLY R et al: Phase I trial of adozelesin using the treatment schedule of daily x 5 every three weeks. Invest. New Drugs (1996) 13:321–326.
   PubMed Web of Science ®Google Scholar
• FLEMING GE RATAIN MJ, O 'BRIEN SM, et al: Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J. Nati Cancer Inst. (1994) 86:368–372.
   PubMedGoogle Scholar
• CARTER CA, WAUD WR, LI LH et al:Preclinical antitumour activity of bizelesin in mice. Clin. Caner Res. (1996) 2:1143–1149.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GH, PATNAIK A, HAMMOND LA et al.: A Phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann. Oncol. (2003) 14:775–782.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, ERLICHMAN C, REID JM et al: Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res. (1998) 4:2111–2117.
   PubMedGoogle Scholar
• CAO P-R, MCHUGH MM, MELENDY T et al: The DNA minor groove alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells. Mol. Cancer Therap. (2003) 2:651–659.
   PubMed Web of Science ®Google Scholar
• GREGSON SJ, HOWARD PW, CORCORAN KE et al: Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo [1,4]benzodiazepines. Bioorg. Med. Chem. Lett. (2000) 10:1845–1847.
   PubMed Web of Science ®Google Scholar
• GREGSON SJ, HOWARD PW, BARCELLA S et al: Effect of C2/C3-entio unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo [2,1-[1,4]benzodiazepines. Bioorg. Med. Chem. Lett. (2000) 10:1849–1851.
   PubMedGoogle Scholar
• GREGSON SJ, HOWARD PW, HARTLEY JA et al.:DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. I Med. Chem. (2001) 44:737–748.
   PubMed Web of Science ®Google Scholar
• SMELLIE M, BOSE DS, THOMPSON AS et al.: Sequence selective recognition of DNA duplex through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine (PBD) dimers. Biochemistry (2003) 8232–8239.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GP, TAYLOR JP, SHNYDER S et al.: Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence selective pyrrolobenzodiazepine (PBD) dimer DNA cross-finking agent. Investig. New Drugs (2004) 22:231–240.
   PubMed Web of Science ®Google Scholar
• GREGSON SJ, HOWARD PW, GULLICK DR et al.: Linker length modulates DNA cross-linking reactivity and cytotoxicity of C8/C8' ether-linked C2-exo-unsaturated pyrrolo [2,1-[1,4]benzodiazepine diners. I Med. Chem. (2004) 47:1161–1174.
   PubMed Web of Science ®Google Scholar
• HARTLEY JA, SPANSWICK VJ, BROOKS N et al: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. in press.
   Google Scholar
• ALLEY MC, HOLLINGSHEAD MG, PACULA-COX CM et al: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 2: efficacy evaluations. Cancer Res. in press.
   Google Scholar
• PEPPER CJ, HAMBLY RM, FEGAN CD, THURSTON DE: The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-CLL cells with evidence of a p53-independent mechanism of cell kill. Cancer Res. in press.
   Google Scholar
• RUCKER VC, FOISTER S, MELANDER C et al.: Sequence specific fluorescence detection of double strand DNA. J. Am. Chem. Soc. (2003) 125:1195–1202.
   PubMed Web of Science ®Google Scholar
• BUERLI RW, MCMINN D, KAIZERMAN JA et al: DNA binding ligands targeting drug-resistant Gram-positive bacteria. Partl: Internal benzimidazole derivatives. Bioorg. Med. Chem. Lett. (2004) 14:1253–1257;
   PubMed Web of Science ®Google Scholar
• BUERLI RW, JONES P, MCMINN D, et al.: DNA binding ligands targeting drug resistant Gram-positive bacteria. Part 2: C-terminal benzimadazoles and derivatives. Bioorg . Med. Chem. Lett. (2004) 14:1259–1263.
   Google Scholar
• BUERLI RW, KAIZERMAN JA, DUAN J-X et al: DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids. Bioorg. Med. Chem. Lett. (2004) 14:2067–2072.
   PubMed Web of Science ®Google Scholar